Supplemental material for "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)"

Supplemental material for Lebwohl, et al., "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)," J Am Acad Dermatol, 2020

Lebwohl等所著《伴与不伴代谢综合征的银屑病患者中替达克珠单抗（Tildrakizumab）的疗效、药物留存率与安全性相当：两项3期随机对照试验（reSURFACE 1与reSURFACE 2）的长期结果》的补充资料，该论文发表于《美国皮肤病学会杂志》（J Am Acad Dermatol）2020年。